Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc.(HUMA) Shareholders
NEW YORK, NY / ACCESSWIRE / November 27, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a ...
Outlook Therapeutics stock craters as the wet AMD drug fails Phase III trial
The Norse Eight trial was part of the data requested by the FDA after the agency rejected the BLA for the company’s Lytenava ...
Outlook Therapeutics reports preliminary results from Norse Eight trials
Outlook Therapeutics (OTLK) announced preliminary topline results of Norse Eight, the second of two adequate and well controlled clinical ...
MarketWatch14h
Outlook Therapeutics Trial of Eye Disease Treatment Misses Key Endpoint
Outlook Therapeutics will resubmit a biologics license application for its ophthalmic formulation of bevacizumab early next year after the second of two clinical trials missed a key target. The ...
Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial
Final efficacy data expected in January 2025Anticipate resubmission of BLA in calendar Q1 2025 ISELIN, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company that ...